As we start to populate and organize the education sessions for the 2018 ISPE Annual Meeting & Expo, I think back to my experiences at the 2017 ISPE Annual Meeting & Expo. We had exposure to global regulators and were able to hear about news and their priorities from a diverse global perspective in a townhall setting. Even more useful was the opportunity to mingle with those regulators during breaks to pick their brains on a variety of topics. This informal access to regulators is a unique opportunity.
We were also exposed to industry leading edge technology that is reshaping our businesses. This included continuous processing which seems to be gaining interest and momentum in many places but with significant issues yet to be institutionalized. There was a presentation by a firm that had converted an approved licensed small molecule from batch to continuous processing. In another session, opportunities to consider continuous processing of biotech large molecules reviewed typical unit operations and how each might go from traditional batch to a continuous step. One firm presented development data used to justify going to a continuous chromatography operation. This was an exciting peek into the future of pharmaceutical manufacturing game changers.
There also were sessions that provided guidance on efficiency gains. One session I attended focused on a true risk managed approach to quality deviations. This presentation addressed a common issue – lots of deviations that are treated with the same rigger, consuming lots of resources, with many closing near or at times beyond their deadlines. Using a quick checklist approach based on risk management principles allows firms to identify those that have the greatest potential for real product impact and to focus resources on those and set realistic target dates. Those with little to no impact can be closed in a more efficient manner.
Our goal is to continue to provide these and more exciting educational experiences at the 2018 ISPE Annual Meeting & Expo in Philadelphia, Pennsylvania USA in the fall. Submissions are coming in and the difficult job to evaluate and select the best has started. Come and network with the leaders in the Pharmaceutical industry and learn from those leading the way to the next evolution (Pharma 4.0).
The ISPE Annual Meeting & Expo is where the industry gathers to address top pharmaceutical priorities and drive innovation. Join us in Philadelphia for the 2018 ISPE Annual Meeting & Expo as we share best practices for navigating organizational and regulatory complexities that advance patient therapies.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...